Abstract
Background: Chromene and anilinopyrimidine heterocyclics are attractive anticancer compounds that have inspired many researchers to design novel derivatives bearing improved anticancer activity.
Methods: A series of pyrimidine-fused benzo[f]chromene derivatives 6a-x were synthesized as anticancer hybrids of 1H-benzo[f]chromenes and anilinopyrimidines. The inhibitory activity of the synthesized compounds 6a-x against cell viability of human chronic myelogenous leukemia (K562), human acute lymphoblastic leukemia (MOLT-4) and human breast adenocarcinoma (MCF-7) cell lines was evaluated using MTT assay. The interaction of the most promising compound with calf-thymus DNA was also studied using spectrometric titrations and Circular Dichroism (CD) spectroscopy.
Results: Most compounds showed promising activity against tested cell lines. Among them, 2,4- dimethoxyanilino derivative 6g exhibited the best profile of activity against tested cell lines (IC50s = 1.6-6.1 μM) with no toxicity against NIH3T3 normal cell (IC50 >200 μM). The spectrometric studies exhibited that compound 6g binds to DNA strongly and may change DNA conformation significantly, presumably via a groove binding mechanism.
Conclusion: The results of this study suggest that the prototype compound 6g can be considered as a novel lead compound for the design and discovery of novel anticancer agents.
Keywords: Anti-cancer activity, benzo[f]chromene, polycyclic compounds, multi-component reactions, DNA-binding, aminopyrimidine derivatives.
Graphical Abstract
[http://dx.doi.org/10.1038/s41392-017-0004-3] [PMID: 29560283]
[http://dx.doi.org/10.2174/0929867325666180607094856] [PMID: 29874992]
[http://dx.doi.org/10.1590/0001-3765201820170823] [PMID: 29768576]
[http://dx.doi.org/10.1111/j.1747-0285.2011.01175.x] [PMID: 21740531]
[http://dx.doi.org/10.1016/j.ejmech.2014.03.049] [PMID: 24681979]
[http://dx.doi.org/10.1007/s12272-012-1208-2] [PMID: 23263805]
[http://dx.doi.org/10.1016/j.ejmech.2012.10.044] [PMID: 23202485]
[http://dx.doi.org/10.1016/j.ejmech.2013.07.014] [PMID: 23973822]
[http://dx.doi.org/10.1016/j.tet.2010.04.024]
[http://dx.doi.org/10.1515/znc-2016-0139] [PMID: 27831925]
[http://dx.doi.org/10.2174/1871520616666160627090249] [PMID: 27357544]
[http://dx.doi.org/10.3389/fchem.2017.00101] [PMID: 29250520]
[http://dx.doi.org/10.1038/srep16750] [PMID: 26568452]
[http://dx.doi.org/10.1021/ja0567485] [PMID: 16478150]
[http://dx.doi.org/10.1016/j.ejmech.2016.12.037] [PMID: 28039771]
[http://dx.doi.org/10.1016/j.cclet.2014.03.048]
[http://dx.doi.org/10.1021/cc900143h] [PMID: 19954208]
[http://dx.doi.org/10.1016/j.cej.2014.03.035]
[http://dx.doi.org/10.3184/174751912X13264750348839]
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[http://dx.doi.org/10.1166/jbn.2012.1451] [PMID: 23030005]
[http://dx.doi.org/10.1016/j.ejmech.2010.02.040] [PMID: 20231044]
[http://dx.doi.org/10.1016/j.ultrasmedbio.2005.09.016] [PMID: 16364806]
[http://dx.doi.org/10.1080/15257770.2018.1515440] [PMID: 30922151]
[http://dx.doi.org/10.2174/18715206113139990142] [PMID: 23387974]
[http://dx.doi.org/10.1021/ja00018a019]
[http://dx.doi.org/10.1016/j.saa.2009.03.017] [PMID: 19380247]
[http://dx.doi.org/10.1021/ic00065a020]
[http://dx.doi.org/10.1155/2009/347872] [PMID: 19830248]